# Best-Link

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/best-link

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.bestlinkbio.com/
- Total disclosed funding: $88M
- Latest round: Series C (May 17, 2026)
- Investors on record: 9

## About

Based in Shanghai, China and founded in 2021, Shanghai Best-Link Bioscience LLC, trading as Best-Link, focuses on the development of novel nano-conjugate drugs and precise nano-drug delivery platforms based on advanced conjugation technology and nanotechnology to develop innovative drugs for precision cancer treatment and tumor immunotherapy. It has submitted more than 10 invention patent applications through independent research and development as of 2023. In May 2026, Best-Link raised CNY 400 million in series C funding from TopAlliance.

The company is dedicated to creating a drug coupling platform and a drug precision delivery platform based on advanced drug linkage technology to develop innovative drugs for oncology precision therapy and oncology immunotherapy.

The company's revenue is generated by providing nano-conjugate drugs.

The company will use the latest funding to accelerate the global development of its core clinical pipeline, expand its international clinical layout, enhance its industrialization capabilities, and further promote the expansion of its innovative product pipeline, helping the company fully implement its globalization strategy in the field of nano-conjugate drugs.

## Funding rounds

- Series C, May 17, 2026, $59M — TopAlliance
- Series B, Dec 11, 2025 — Yonghua Capital, TEDA Venture Capital, Casstar Capital, Lapam Capital, Hongcheng Investment Management, Beijing Sun-Novo Pharmaceutical Research
- Series A, Apr 6, 2023, $29M — Lapam Capital, Hyfinity Investments, TigerYeah Capital

## Investors

- Lapam Capital (https://capitalatlas.ai/funds/lapam-capital) — Series A, Series B
- Hyfinity Investments (https://capitalatlas.ai/funds/hyfinity-investments) — Series A
- TigerYeah Capital (https://capitalatlas.ai/funds/tigeryeah-capital) — Series A
- Yonghua Capital (https://capitalatlas.ai/funds/yonghua-capital) — Series B
- TEDA Venture Capital (https://capitalatlas.ai/funds/teda-venture-capital) — Series B
- Casstar Capital (https://capitalatlas.ai/funds/casstar-capital) — Series B
- Hongcheng Investment Management (https://capitalatlas.ai/funds/hongcheng-investment-management) — Series B
- Beijing Sun-Novo Pharmaceutical Research — Series B
- TopAlliance (https://capitalatlas.ai/funds/topalliance) — Series C